MX2011013288A - Agentes antimicrobianos. - Google Patents
Agentes antimicrobianos.Info
- Publication number
- MX2011013288A MX2011013288A MX2011013288A MX2011013288A MX2011013288A MX 2011013288 A MX2011013288 A MX 2011013288A MX 2011013288 A MX2011013288 A MX 2011013288A MX 2011013288 A MX2011013288 A MX 2011013288A MX 2011013288 A MX2011013288 A MX 2011013288A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- present
- gram
- nucleic acid
- acid molecules
- Prior art date
Links
- 239000004599 antimicrobial Substances 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente invención se refiere a agentes antimicrobianos contra bacterias Gramnegativas, en particular a proteínas de fusión compuestas de una enzima que tiene la actividad de degradar la pared celular de bacterias Gramnegativas y a un tramo de péptido adicional fusionado a la enzima en el N o C-terminal. Además, la presente invención se refiere a moléculas de ácido nucleico que codifican para la proteína de fusión, vectores que comprenden las moléculas de ácido nucleico y células hospederas que comprenden ya sea las moléculas de ácido nucleico o los vectores. Además, la presente invención se refiere a la proteína de fusión para usarse como un medicamento, en particular para el tratamiento o prevención de infecciones bacterianas Gramnegativas, como medio de diagnóstico o como sustancia cosmética. La presente invención se refiere también al tratamiento y prevención de la contaminación por bacterias Gramnegativas de alimentos, de equipo de procesamiento de alimentos, de plantas procesadoras de alimentos, de superficies que entran en contacto con alimentos, de dispositivos médicos, de superficies en hospitales y quirófanos. Más aún, la presente invención se refiere a composiciones farmacéuticas o cosméticas que comprenden la proteína de fusión.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09163953 | 2009-06-26 | ||
PCT/EP2010/059146 WO2010149792A2 (en) | 2009-06-26 | 2010-06-28 | Antimicrobial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011013288A true MX2011013288A (es) | 2012-02-28 |
Family
ID=42799668
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011013288A MX2011013288A (es) | 2009-06-26 | 2010-06-28 | Agentes antimicrobianos. |
MX2015006025A MX360300B (es) | 2009-06-26 | 2010-06-28 | Agentes antimicrobianos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015006025A MX360300B (es) | 2009-06-26 | 2010-06-28 | Agentes antimicrobianos. |
Country Status (18)
Country | Link |
---|---|
US (3) | US8906365B2 (es) |
EP (3) | EP3714895A3 (es) |
JP (2) | JP6034187B2 (es) |
KR (2) | KR20170024129A (es) |
CN (2) | CN105440139B (es) |
AU (3) | AU2010264656B2 (es) |
BR (1) | BRPI1015192A2 (es) |
CA (1) | CA2764131C (es) |
DK (1) | DK2445515T3 (es) |
EA (1) | EA037202B1 (es) |
ES (1) | ES2579806T3 (es) |
HK (1) | HK1169311A1 (es) |
IL (2) | IL217124A (es) |
MX (2) | MX2011013288A (es) |
PL (1) | PL2445515T3 (es) |
SG (1) | SG177370A1 (es) |
SI (1) | SI2445515T1 (es) |
WO (1) | WO2010149792A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0815484D0 (en) | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
ES2579806T3 (es) | 2009-06-26 | 2016-08-16 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Agentes antimicrobianos |
WO2010149795A1 (en) | 2009-06-26 | 2010-12-29 | Lysando Holding Establishment | Antimicrobial agents |
CA2772001A1 (en) * | 2009-08-24 | 2011-03-03 | Katholieke Universiteit Leuven, K.U. Leuven R&D | New endolysin obpgplys |
CA2794603C (en) * | 2010-04-27 | 2019-05-21 | Lysando Ag | Method of reducing biofilms |
EP2468856A1 (en) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
EP2697387B1 (en) | 2011-04-12 | 2021-09-15 | Bactoclear Holdings PTE. LTD. | Chimeric antibacterial polypeptides |
US9068204B2 (en) | 2013-03-15 | 2015-06-30 | The United States Of America, As Represented By The Secretary Of Agriculture | Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation |
WO2015070912A1 (en) * | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
WO2015070911A1 (en) * | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified kz144 endolysin sequence |
US10329550B2 (en) | 2014-02-14 | 2019-06-25 | Lysando Ag | Antimicrobial agents |
WO2015155244A1 (en) * | 2014-04-08 | 2015-10-15 | Lysando Ag | Pharmaceutical composition against chronic bacterial infections |
ES2767294T3 (es) * | 2014-06-26 | 2020-06-17 | Univ Rockefeller | Lisinas de Acinetobacter |
CN105734029B (zh) * | 2014-12-12 | 2020-09-25 | 丰益(上海)生物技术研发中心有限公司 | 磷脂酶抗菌肽 |
JP7029805B2 (ja) | 2015-09-17 | 2022-03-04 | コントラフェクト コーポレイション | グラム陰性菌に対して活性を有する溶解素ポリペプチド |
CN105175509A (zh) * | 2015-10-19 | 2015-12-23 | 河南科技学院 | 一种抗菌肽xyz-1及其应用 |
WO2017151617A1 (en) * | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
WO2017186942A1 (en) * | 2016-04-28 | 2017-11-02 | Lysando Ag | Antimicrobial agents against salmonella bacteria |
WO2018100408A1 (en) * | 2016-11-30 | 2018-06-07 | Sasinapas Co.,Ltd. | Modified peptides |
CN110300760B (zh) * | 2016-12-16 | 2023-10-20 | 米尼奥大学 | 新的内溶素 |
US20180208938A1 (en) * | 2017-01-23 | 2018-07-26 | Innate Immunity LLC | Compositions and Methods for Protecting Plants Against Bacterial Infections |
CA3059019A1 (en) * | 2017-04-03 | 2018-10-11 | Sasinapas Co., Ltd. | Engineered gram-negative endolysins |
US11325955B2 (en) | 2017-07-19 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
WO2019155002A1 (en) * | 2018-02-08 | 2019-08-15 | Institut Pasteur | Anti-prevotella bacteriocin methods and compositions |
KR20200136980A (ko) * | 2018-03-29 | 2020-12-08 | 콘트라펙트 코포레이션 | 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도 |
CN108410840A (zh) * | 2018-04-03 | 2018-08-17 | 大连理工大学 | 一种铜绿假单胞菌噬菌体内溶素及其编码基因与应用 |
JP6979210B2 (ja) * | 2018-04-26 | 2021-12-08 | 株式会社ニューギン | 遊技機 |
CN112166190A (zh) * | 2018-05-30 | 2021-01-01 | 莱桑多公司 | 新抗微生物蛋白 |
AU2019276252A1 (en) * | 2018-05-30 | 2020-11-26 | Lysando Ag | Novel antimicrobial fusion proteins |
US20210363511A1 (en) * | 2018-08-23 | 2021-11-25 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
JP2023517245A (ja) | 2020-03-11 | 2023-04-24 | テラム セラピューティクス エセ.エレ. | 新たな組換え溶解素及びグラム陰性細菌感染の治療におけるその使用 |
CA3171721A1 (en) | 2020-03-19 | 2021-09-23 | Fritz Eichenseher | A stabilized protein of interest |
KR102286544B1 (ko) * | 2021-02-10 | 2021-08-05 | 주식회사 라이센텍 | 융합 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제 |
CA3184447A1 (en) * | 2020-05-22 | 2021-11-25 | Lysentech Co., Ltd. | Novel polypeptide, fusion polypeptide, and antibiotic against gram-negative bacteria comprising same |
WO2022011434A1 (en) * | 2020-07-17 | 2022-01-20 | The University Of Western Australia | Compositions and methods for the treatment of cancer |
CN111876400B (zh) * | 2020-08-06 | 2022-05-24 | 昆明理工大学 | 一种常温裂解酶Sly和编码此酶的多核苷酸 |
SK289101B6 (sk) * | 2020-12-17 | 2023-08-09 | Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia | Antimikrobiálny proteín, antimikrobiálny rekombinantný proteín s lytickými vlastnosťami, expresný vektor, spôsob ich prípravy a použitie |
US11548917B1 (en) * | 2021-11-24 | 2023-01-10 | Intron Biotechnology, Inc. | Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same |
CN117534733B (zh) * | 2024-01-10 | 2024-03-29 | 黑龙江八一农垦大学 | 抗菌肽cm24、重组基因、乳酸工程菌及其应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR970006154B1 (ko) | 1987-07-06 | 1997-04-24 | 루이지아나 스테이트 유니버시티 아그리컬춰럴 앤드 메카니칼 컬리지 | 용해성 펩티드에 의한 진핵 병원체와 신생물의 억제 및 섬유아세포와 임파구의 자극 |
GB8816693D0 (en) | 1988-07-13 | 1988-08-17 | Agricultural & Food Res | Viral enzyme & gene |
GB2255561B (en) | 1991-04-20 | 1995-06-21 | Agricultural & Food Res | Lysins from bacteriophages |
JPH08501213A (ja) * | 1992-08-21 | 1996-02-13 | ザ ユニバーシティー オブ ブリティッシュ コロンビア | カチオン性ペプチド及びその製造方法 |
AU3341995A (en) * | 1994-09-01 | 1996-03-22 | Novo Nordisk A/S | A basic protein composition for killing or inhibiting microbial cells |
US6503881B2 (en) | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US6428784B1 (en) | 1997-10-31 | 2002-08-06 | New Horizons Diagnostics Corp | Vaginal suppository for treating group B Streptococcus infection |
US20030113298A1 (en) * | 1997-10-31 | 2003-06-19 | Vincent Fischetti | Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses |
US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
US6288212B1 (en) * | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
US5993809A (en) | 1998-11-18 | 1999-11-30 | Children's Hospital Medical Center | Lysozyme fusion proteins in infections |
EP1194570A1 (en) * | 1999-06-23 | 2002-04-10 | PPL Therapeutics (Scotland) Limited | Fusion proteins incorporating lysozyme |
US7338936B2 (en) * | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
DE60329382D1 (de) | 2002-04-22 | 2009-11-05 | Dow Global Technologies Inc | Kostengünstige herstellung von peptiden |
US7566447B2 (en) * | 2003-05-15 | 2009-07-28 | Iogenetics, Llc | Biocides |
US7935501B2 (en) * | 2003-09-11 | 2011-05-03 | Novozymes Pharma Biotec A/S | Recombinant production of antimicrobial peptides |
WO2005108563A2 (en) * | 2004-04-19 | 2005-11-17 | University Of Chicago | Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4 |
US20070207209A1 (en) * | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
US7572602B1 (en) | 2004-12-03 | 2009-08-11 | The United States Of America As Represented By The Secretary Of Agriculture | Nucleic acid encoding endolysin fusion protein |
DE102005040347A1 (de) | 2005-08-25 | 2007-03-01 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien |
US7943128B2 (en) | 2006-03-31 | 2011-05-17 | The University Court Of The University Of St Andrews | Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase |
DE102006061002A1 (de) | 2006-12-22 | 2008-06-26 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien |
MX340736B (es) * | 2007-09-25 | 2016-07-22 | Pastoral Greenhouse Gas Res Ltd * | Vacunas y componentes de vacunas para inhibicion de celulas microbianas. |
US20100310522A1 (en) | 2007-11-26 | 2010-12-09 | Plant Bioscience Limited | Novel Polypeptides Having Endolysin Activity and Uses Thereof |
EP2318531A4 (en) | 2008-07-24 | 2011-11-09 | Us Agriculture | TO RESISTANCE DEVELOPMENT REFRACTORY ANTIMICROBIAL ACTIVE SUBSTANCES |
EP2157100A1 (en) | 2008-08-19 | 2010-02-24 | Profos AG | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
GB0815484D0 (en) | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
WO2010091078A2 (en) * | 2009-02-03 | 2010-08-12 | Danfoss Aquaz A/S | Nanofabricated membrane using polymerized proteoliposomes |
US8389679B2 (en) | 2009-02-05 | 2013-03-05 | The Regents Of The University Of California | Targeted antimicrobial moieties |
US8383102B2 (en) | 2009-05-21 | 2013-02-26 | The United States Of America As Represented By The Secretary Of Agriculture | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens |
ES2579806T3 (es) | 2009-06-26 | 2016-08-16 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Agentes antimicrobianos |
WO2010149795A1 (en) | 2009-06-26 | 2010-12-29 | Lysando Holding Establishment | Antimicrobial agents |
CA2772001A1 (en) | 2009-08-24 | 2011-03-03 | Katholieke Universiteit Leuven, K.U. Leuven R&D | New endolysin obpgplys |
CA2794603C (en) | 2010-04-27 | 2019-05-21 | Lysando Ag | Method of reducing biofilms |
US9388400B2 (en) | 2012-06-29 | 2016-07-12 | Lysando Ag | Composition for use in mycobacteria diagnosis |
-
2010
- 2010-06-28 ES ES10730139.2T patent/ES2579806T3/es active Active
- 2010-06-28 SG SG2011096310A patent/SG177370A1/en unknown
- 2010-06-28 US US13/380,312 patent/US8906365B2/en active Active
- 2010-06-28 CN CN201510751765.3A patent/CN105440139B/zh active Active
- 2010-06-28 JP JP2012516776A patent/JP6034187B2/ja active Active
- 2010-06-28 BR BRPI1015192A patent/BRPI1015192A2/pt not_active IP Right Cessation
- 2010-06-28 PL PL10730139.2T patent/PL2445515T3/pl unknown
- 2010-06-28 MX MX2011013288A patent/MX2011013288A/es active IP Right Grant
- 2010-06-28 EP EP20158514.8A patent/EP3714895A3/en active Pending
- 2010-06-28 WO PCT/EP2010/059146 patent/WO2010149792A2/en active Application Filing
- 2010-06-28 CA CA2764131A patent/CA2764131C/en active Active
- 2010-06-28 CN CN201080028371.0A patent/CN102458452B/zh active Active
- 2010-06-28 KR KR1020177004886A patent/KR20170024129A/ko active Search and Examination
- 2010-06-28 MX MX2015006025A patent/MX360300B/es unknown
- 2010-06-28 SI SI201031217A patent/SI2445515T1/sl unknown
- 2010-06-28 DK DK10730139.2T patent/DK2445515T3/en active
- 2010-06-28 EP EP16163433.2A patent/EP3058950B1/en active Active
- 2010-06-28 AU AU2010264656A patent/AU2010264656B2/en active Active
- 2010-06-28 EP EP10730139.2A patent/EP2445515B1/en active Active
- 2010-06-28 KR KR1020127002107A patent/KR101711062B1/ko active IP Right Grant
- 2010-06-28 EA EA201270079A patent/EA037202B1/ru not_active IP Right Cessation
-
2011
- 2011-12-21 IL IL217124A patent/IL217124A/en active IP Right Grant
-
2012
- 2012-10-09 HK HK12109879.3A patent/HK1169311A1/zh unknown
-
2014
- 2014-11-07 US US14/535,457 patent/US10137175B2/en active Active
-
2016
- 2016-04-13 AU AU2016202296A patent/AU2016202296B2/en active Active
- 2016-06-07 JP JP2016113291A patent/JP2017008033A/ja active Pending
-
2017
- 2017-03-05 IL IL250938A patent/IL250938B/en active IP Right Grant
-
2018
- 2018-03-16 AU AU2018201931A patent/AU2018201931B2/en active Active
- 2018-10-24 US US16/169,472 patent/US11052137B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011013288A (es) | Agentes antimicrobianos. | |
MX2011013453A (es) | Agentes antimicrobianos. | |
MX344257B (es) | Agentes antimicrobianos. | |
AU2010288559A8 (en) | New endolysin OBPgpLYS | |
GB201018518D0 (en) | Novel endolysin | |
WO2010023207A3 (en) | Antimicrobial agents | |
Mercer et al. | Antimicrobial susceptibility testing of antimicrobial peptides to better predict efficacy | |
MX2012012345A (es) | Metodo de reduccion de biopeliculas. | |
Pane et al. | Identification of novel cryptic multifunctional antimicrobial peptides from the human stomach enabled by a computational–experimental platform | |
Briers et al. | Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria | |
JP2014500714A5 (es) | ||
JP2012530510A5 (es) | ||
EA201991233A1 (ru) | Новый эндолизин | |
NZ603200A (en) | Peptides and their use | |
JP2012530509A5 (es) | ||
WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
Gudmundsdóttir et al. | Potential use of Atlantic cod trypsin in biomedicine | |
KR102573154B1 (ko) | 변성 펩티드 | |
EP3313862B9 (en) | Broad-spectrum anti-infective peptides | |
Ho et al. | Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies | |
Garvey | Medical device-associated healthcare infections: sterilization and the potential of novel biological approaches to ensure patient safety | |
Heinzinger et al. | Evaluating the translational potential of bacteriocins as an alternative treatment for Staphylococcus aureus infections in animals and humans | |
Lewies | An in vitro evaluation of the antibacterial and anticancer properties of the antimicrobial peptide nisin Z | |
TH120357B (th) | สารต้านจุลินทรีย์ | |
TH120358B (th) | สารต้านจุลินทรีย์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: GALDERMA RESEARCH & DEVELOPMENT |
|
FG | Grant or registration |